103482-25-3 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
2,6-dichlorobenzylsulfonamide is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Antiseptic and Disinfectant Formulations:
Leveraging its antimicrobial properties, 2,6-dichlorobenzylsulfonamide is used as an active ingredient in antiseptic and disinfectant formulations, helping to prevent infections and maintain hygiene in various settings.
Used in Polymer Production:
2,6-dichlorobenzylsulfonamide is utilized in the production of various types of polymers, contributing to the development of new materials with specific properties for different applications.
Used as a Corrosion Inhibitor in Cooling Water Systems:
Due to its chemical properties, 2,6-dichlorobenzylsulfonamide is employed as a corrosion inhibitor in cooling water systems, helping to protect equipment and extend their lifespan.
Safety Precautions:
Given the potential health hazards associated with 2,6-dichlorobenzylsulfonamide, it is crucial to handle and use this chemical compound with caution and in accordance with safety guidelines to minimize risks and ensure safe working conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 103482-25-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,4,8 and 2 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 103482-25:
(8*1)+(7*0)+(6*3)+(5*4)+(4*8)+(3*2)+(2*2)+(1*5)=93
93 % 10 = 3
So 103482-25-3 is a valid CAS Registry Number.
103482-25-3Relevant academic research and scientific papers
IL-8 receptor antagonists
-
, (2008/06/13)
This invention relates to novel spiro compound derivatives of benzoisothiazolyl-urea and -thiourea and compositions thereof. These compounds are useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU)
Ludovici, Donald W.,Kukla, Michael J.,Grous, Philip G.,Krishnan, Suma,Andries, Koen,De Bethune, Marie-Pierre,Azijn, Hilde,Pauwels, Rudi,De Clercq, Erik,Arnold, Edward,Janssen, Paul A.J.
, p. 2225 - 2228 (2007/10/03)
Stemming from work on a previous clinical candidate, loviride, and other α-APA derivatives, a new series of potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been synthesized. The ITU analogues, which contain a unique diarylated imidoyl thiourea, are very active in inhibiting both wild-type and clinically important mutant strains of HIV-1.
